Novel pharmacological agents in clinical development for solid tumours

G. K. Dy; P. Haluska; A. A. Adjei

doi:10.1517/13543784.10.12.2059

Novel pharmacological agents in clinical development for solid tumours

G. K. Dy, P. Haluska, A. A. Adjei

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.

Original language	English (US)
Pages (from-to)	2059-2088
Number of pages	30
Journal	Expert Opinion on Investigational Drugs
Volume	10
Issue number	12
DOIs	https://doi.org/10.1517/13543784.10.12.2059
State	Published - 2001

Keywords

Angiogenesis
Antisense oligonucleotide
Cyclin-dependent kinase
Extracellular matrix
Farnesyltransferase inhibitors
Heat shock protein
Monoclonal antibodies
Proteasome
Protein kinase C inhibitors
Ras
Receptor tyrosine kinase inhibitors
Signal transduction
Ubiquitin

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/13543784.10.12.2059

Cite this

@article{07e5e19153b74e009eb7eb2703ce7104,

title = "Novel pharmacological agents in clinical development for solid tumours",

abstract = "For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.",

keywords = "Angiogenesis, Antisense oligonucleotide, Cyclin-dependent kinase, Extracellular matrix, Farnesyltransferase inhibitors, Heat shock protein, Monoclonal antibodies, Proteasome, Protein kinase C inhibitors, Ras, Receptor tyrosine kinase inhibitors, Signal transduction, Ubiquitin",

author = "Dy, {G. K.} and P. Haluska and Adjei, {A. A.}",

year = "2001",

doi = "10.1517/13543784.10.12.2059",

language = "English (US)",

volume = "10",

pages = "2059--2088",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "12",

}

TY - JOUR

T1 - Novel pharmacological agents in clinical development for solid tumours

AU - Dy, G. K.

AU - Haluska, P.

AU - Adjei, A. A.

PY - 2001

Y1 - 2001

N2 - For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.

AB - For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.

KW - Angiogenesis

KW - Antisense oligonucleotide

KW - Cyclin-dependent kinase

KW - Extracellular matrix

KW - Farnesyltransferase inhibitors

KW - Heat shock protein

KW - Monoclonal antibodies

KW - Proteasome

KW - Protein kinase C inhibitors

KW - Ras

KW - Receptor tyrosine kinase inhibitors

KW - Signal transduction

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=0035218360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035218360&partnerID=8YFLogxK

U2 - 10.1517/13543784.10.12.2059

DO - 10.1517/13543784.10.12.2059

M3 - Review article

C2 - 11772306

AN - SCOPUS:0035218360

SN - 1354-3784

VL - 10

SP - 2059

EP - 2088

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 12

ER -

Novel pharmacological agents in clinical development for solid tumours

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this